Biotech

All Articles

AN 2 fifty percents head count, quits stage 3 test after records disappoint

.AN2 Therapies is reassessing its business in feedback to lackluster midphase information, promising...

Merck pays for $700M for bispecific, snooping autoimmune opening and odds to test Amgen in cancer

.Merck &amp Co. is actually paying out $700 million in advance to test Amgen in a blood stream cance...

Gilead pays out J&ampJ $320M to exit licensing package for seladelpar

.Along With Gilead Sciences on the verge of an FDA decision for its own liver health condition medic...

' All palms on deck' at Lilly as peers target obesity market

.CEO David Ricks can easily view the providers putting together tents at basecamp behind Eli Lilly i...

Entero laying off personnel, leaving workplace and pausing R&ampD

.Bed Liquidators has transformed Entero Therapeutics white as a sheet. The lender bought Entero to s...

Exelixis loses ADC after determining it's no match for Tivdak

.Exelixis is surrendering on its tissue factor (TF)- targeting antibody-drug conjugate after conclud...

Relay dislikes SHP2 inhibitor after Genentech leaves

.3 weeks after Roche's Genentech system bowed out an SHP2 inhibitor contract, Relay Therapeutics has...

Stoke's Dravet disorder med discharged of predisposed scientific grip

.Stoke Therapeutics' Dravet disorder medication has been devoid of a predisposed hold, clearing the ...

Fierce Biotech's Gabrielle Masson shows Brutal 15 at NYSE

.Brutal Biotech Partner Publisher Gabrielle Masson offered the 2024 class of Strong 15 victors on th...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has actually axed its own once-monthly double GLP-1/ GIP receptor agonist, finishing (...